Cardiac Safety of Indacaterol

A Randomized, Multiple-dose, Placebo- and Positive-controlled Parallel Group Study to Evaluate the Effects of Indacaterol on Cardiac Safety in Healthy Subjects

This study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.

Inclusion Criteria:

• Healthy, non-smoking
• Body mass index (BMI) 18.5-32 kg/m2
• Body weight at least 50 kg

Exclusion Criteria:

• Recent/concurrent use of concomitant medications (except acetaminophen)
• Recent participation in other clinical trials
• Recent donation or loss of blood
• History/presence of a range of medical conditions, including electrocardiographic (ECG) abnormalities, diabetes mellitus, hyperthyroidism and impaired renal function

Other protocol-defined inclusion/exclusion criteria may apply